Table 2.
Clinical and PET characteristics of different PTCL subtypes
| Characteristics | PTCL-NOS | AITL | ALCL (ALK−) |
|---|---|---|---|
| Sex: female/male | 18/29 | 9/21 | 3/4 |
| Age: ≤ 60 years/> 60 years | 25/22 | 12/18 | 6/1 |
| LDH: normal/higher than normal | 26/21 | 9/21 | 3/4 |
| B symptoms: no/yes | 21/26 | 8/22 | 4/3 |
| ECOG performance status: 0–1/> 1 | 29/18 | 21/9 | 7/0 |
| Ann Arbor stage: I–II/III–IV | 10/37 | 2/28 | 3/4 |
| Extranodal sites ≥ 2: no/yes | 33/14 | 25/5 | 7/0 |
| BMB: negative/positive | 35/12 | 22/8 | 6/1 |
| Ki-67 ≥ 80%: no/yes | 35/12 | 22/8 | 6/1 |
| Platelet cell count ≥ 150 × 109/L: no/yes | 24/23 | 22/8 | 2/5 |
| SUVmax | 10.6 (2.6–25.5) | 11.3 (3.9–25.5) | 14.3 (4.3–33.5) |
| TMTV (cm3) | 277.7 (3.4–1334.6) | 521.5 (4.3–1887.0) | 67.8 (3.8–250.0) |
| TLG | 638.1 (10.9–3255.9) | 1825.5 (10.9–6308.0) | 411.1 (14.9–1182.9) |
PTCL-NOS peripheral T-cell lymphoma (PTCL) not otherwise specified, AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large-cell lymphoma, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy